Parkinson’s drug therapies in the clinical trial pipeline: 2024 update
Each year, members of the Cure Parkinson’s research team collaborate with Parkinson’s research advocates and The Michael J. Fox Foundation to present an overview on the current clinical trials landscape for Parkinson’s. The 2024 report, now published in the Journal of Parkinson’s Disease (JPD), marks...
Learn more
2022 Tom Isaacs Award pays tribute to Drs. Michael Okun and Ray Dorsey
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce Dr Ray Dorsey, University of Rochester, and Dr Michael Okun, University of Florida, are joint winners of the 2022 Tom Isaacs Award.
Phase 1 trial results of new GDNF delivery mechanism
The results of a recent clinical trial testing a new way of delivering the nerve growth factor, GDNF, into the brains of people with Parkinson’s demonstrate that it is safe and well tolerated. Glial cell-line derived neurotrophic factor, or GDNF as it is more commonly…
Diet, exercise and Parkinson’s
A recently published large new study provides strong evidence that consuming a healthy diet and engaging in physical activity may improve outcomes for people with Parkinson’s.
World Health Organisation (WHO) launches global strategy for Parkinson’s
The WHO have published a technical brief entitled Parkinson disease: a public health approach, outlining the global burden, treatment gaps and crucial areas for intervention in Parkinson’s.
A sub-study of azathioprine in Parkinson’s
There is increasing evidence that inflammation and the immune system might have contributory roles in the development and progression of Parkinson’s.